News
Advanced BioDesign, member of ENHPATHY consortium
Advanced BioDesign has team up with ENHPATHY, a multidisciplinary, scientific consortium supported by the European Commission, in the effort to open new diagnostic and therapeutic avenues for patients.
About ENPATHYENHPATHY is a multidisciplinary science consortium created in the frame of the Marie Skłodowska-Curie actions (MSCA)-ITN-ETN European Training Networks call and regrouping 14 academic and 9 non-academic European organisations in the continuum of basic, translational and clinical research on enhancers and associated diseases. In genetics, enhancers are short regions of DNA that can be bound by proteins to increase the likelihood that transcription of a particular gene will occur. Although changes in enhancer activity are predicted to have broad pathological and therapeutic implications, there is a limited mechanistic understanding of human enhanceropathies.
ENHPATHY aims to increase scientific knowledge and train the new generation of researchers on the molecular basis of human enhanceropathies to pave the way for development of novel targeted therapies.
